Hoth Therapeutics, Inc. (NASDAQ:HOTH) Short Interest Up 117.4% in December

Hoth Therapeutics, Inc. (NASDAQ:HOTH) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totalling 633,400 shares, an increase of 117.4% from the December 15th total of 291,300 shares. Approximately 9.3% of the company’s stock are sold short. Based on an average daily trading volume, of 8,650,000 shares, the days-to-cover ratio is currently 0.1 days.

Hoth Therapeutics Price Performance

HOTH stock traded up $0.07 during mid-day trading on Thursday, reaching $1.58. The company had a trading volume of 1,180,044 shares, compared to its average volume of 50,088,301. Hoth Therapeutics has a 52 week low of $0.58 and a 52 week high of $3.80. The company has a market capitalization of $10.90 million, a price-to-earnings ratio of -1.20 and a beta of 0.75. The stock has a 50 day simple moving average of $0.97 and a two-hundred day simple moving average of $0.89.

Hoth Therapeutics (NASDAQ:HOTH) last issued its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01). On average, equities analysts predict that Hoth Therapeutics will post -1.18 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Hoth Therapeutics in a research note on Monday, November 4th. D. Boral Capital reissued a “buy” rating and issued a $5.00 price objective on shares of Hoth Therapeutics in a research report on Tuesday, January 7th. Finally, Benchmark reaffirmed a “speculative buy” rating and issued a $3.00 target price on shares of Hoth Therapeutics in a research report on Friday, October 11th.

Institutional Investors Weigh In On Hoth Therapeutics

An institutional investor recently bought a new position in Hoth Therapeutics stock. Virtu Financial LLC acquired a new stake in Hoth Therapeutics, Inc. (NASDAQ:HOTH) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned about 0.47% of Hoth Therapeutics as of its most recent SEC filing. Institutional investors own 7.08% of the company’s stock.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.